Valeant Pharmaceuticals International (VRX) Posts Q1 EPS of $0.02, Tops Revenue Expectations and Raises FY11 Guidance
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Research and development costs, net: 11.95M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Financial Fact:
Research and development costs, net: 11.95M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.02, versus ($0.02) reported last year. Revenue for the quarter came in at $565 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
Earnings, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
